

# TAGLICH BROTHERS

MEMBER: FINRA, SIPC | WWW.TAGLICHBROTHERS.COM

## Final Report

*Investors should consider this report as only a single factor in making their investment decision.*

### Nexeon Medsystems Inc.

### Dropping Coverage

Howard Halpern

March 1, 2019

**NXNN \$2.63 — (OTC)**

	2015 A	2016 A	2017 A
Revenue (in millions)	\$0.0	\$1.5	\$3.4
Earnings (loss) per share*	(\$0.03)	(\$0.59)	(\$1.65)

52-Week range*	\$9.50 – \$1.20	Fiscal year ends:	December
Shares outstanding	2.0 million	Revenue/shares (ttm)	\$5.09
Approximate float	0.8 million	Price/Sales (ttm)	0.5X
Market Capitalization	\$5.3 million	Price/Sales (2019) E	NA
Tangible Book value/shr	(\$0.35)	Price/Earnings (ttm)	NMF
Price/Book	NMF	Price/Earnings (2019) E	NA

\* All per share amounts reflect a 1 for 14 reverse stock-split effective June 28, 2018

Nexeon Medsystems, Inc., headquartered in Dallas, TX, is a global medical device company primarily focused on providing its Viant™ Deep Brain Stimulation product to improve the quality of life for patients suffering from neurological diseases.


#### Key Investment Considerations:

**Taglich Brothers is terminating its research services of Nexeon Medsystems, Inc.**


**Please view our Disclosures on pages 2 – 4.**

790 New York Avenue, Huntington, N.Y. 11743  
(800) 383-8464 • Fax (631) 757-1333

**Price Chart**



**Taglich Brothers Current Ratings Distribution**



30.56 % Buy 61.11 % Hold 6.94 % Not Rated 1.39 % Sell

<b>Investment Banking Services for Companies Covered in the Past 12 Months</b>		
Rating	#	%
Buy	2	8
Hold		
Sell		
Not Rated	2	50

**Important Disclosures**

As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned in this report. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company with in the last three years.

All research issued by Taglich Brothers, Inc. is based on public information. In October 2017, the company paid Taglich Brothers a monetary fee of \$4,500 (USD) representing payment for the creation and dissemination of research reports for three months. From May 2018 to January 2019, the company was obligated to pay Taglich Brothers a monthly monetary fee of \$1,500 (USD) for the creation and dissemination of research reports.

**General Disclosures**

The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance.

**Analyst Certification**

**I, Howard Halpern, the research analyst of this report, hereby certify that the views expressed in this report accurately reflect my personal views about the subject securities and issuers; and that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report.**

**Public Companies mentioned in this report:**

### **Meaning of Ratings**

**Buy** – The growth prospects, degree of investment risk, and valuation make the stock attractive relative to the general market or comparable stocks.

**Speculative Buy** – Long-term prospects of the company are promising but investment risk is significantly higher than it is in our BUY-rated stocks. Risk-reward considerations justify purchase mainly by high risk-tolerant accounts. In the short run, the stock may be subject to high volatility and could continue to trade at a discount to its market.

**Neutral** – Based on our outlook the stock is adequately valued. If investment risks are within acceptable parameters, this equity could remain a holding if already owned.

**Sell** – Based on our outlook the stock is significantly overvalued. A weak company or sector outlook and a high degree of investment risk make it likely that the stock will underperform relative to the general market.

**Dropping Coverage** – Research coverage discontinued due to the acquisition of the company, termination of research services, non-payment for such services, diminished investor interest, or departure of the analyst.

### **Some notable Risks within the Microcap Market**

**Stocks in the Microcap segment of the market have many risks that are not as prevalent in Large-cap, Blue Chips or even Small-cap stocks. Often it is these risks that cause Microcap stocks to trade at discounts to their peers. The most common of these risks is liquidity risk, which is typically caused by small trading floats and very low trading volume which can lead to large spreads and high volatility in stock price. In addition, Microcaps tend to have significant company-specific risks that contribute to lower valuations. Investors need to be aware of the higher probability of financial default and higher degree of financial distress inherent in the microcap segment of the market.**

---

From time to time our analysts may choose to withhold or suspend a rating on a company. We continue to publish informational reports on such companies; however, they have no ratings or price targets. In general, we will not rate any company that has too much business or financial uncertainty for our analysts to form an investment conclusion, or that is currently in the process of being acquired.